The Impact of the Coexpression of MET and ESR Genes on Prognosticators and Clinical Outcomes of Breast Cancer: An Analysis for the METABRIC Dataset
Table 2
Association of the MET/ESR gene expression status with clinicopathologic characteristics in patients with breast cancer.
Parameter
Expression status
value
Expression status
value
(n = 299)
(n = 403)
(n = 591)
(n = 452)
Stage
0.746
0.001
Early
191 (40.6)
280 (59.4)
411 (58.1)
297 (41.9)
Advanced
14 (37.8)
23 (62.2)
27 (37.5)
45 (62.5)
Grade
<0.001
<0.001
I/II
92 (27.2)
246 (72.8)
311 (63.7)
177 (36.3)
III
198 (58.1)
143 (41.9)
255 (49.5)
260 (50.5)
ER
<0.001
<0.001
Positive
150 (28.0)
385 (72.0)
517 (63.7)
295 (36.3)
Negative
146 (92.4)
12 (7.6)
65 (30.1)
151 (69.9)
PR
<0.001
<0.001
Positive
86 (22.8)
291 (77.2)
372 (65.0)
200 (35.0)
Negative
213 (65.5)
112 (34.5)
219 (46.5)
252 (53.5)
HER2
<0.001
0.064
Positive
77 (76.2)
24 (23.8)
58 (48.7)
61 (51.3)
Negative
222 (36.9)
379 (63.1)
533 (57.7)
391 (42.3)
Molecular subtype
<0.001
<0.001
Luminal
70 (17.8)
323 (82.2)
458 (70.4)
193 (29.6)
Non-luminal
229 (74.8)
77 (25.2)
132 (33.9)
257 (66.1)
Data are presented as n(%). Chi-square test. Indicates statistical significance at . ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor.
